A Clinical Trial Evaluating TQB2101 in Subjects With Advanced Hematologic Malignancies

Clinical trial NCT07113925 · RECRUITING

Trial details

NCT number: NCT07113925
Sponsor: Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Status: RECRUITING
Phase: Phase 1
Study type: INTERVENTIONAL

Advanced Hematologic Malignancies

Start date: 2025-08-01
Primary completion: 2025-12-01
Enrollment: 114

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.